African-American patients harbored significantly more tumor-infiltrating lymphocytes than European Americans among early-stage (I to II), but not late-stage (III to IV), patients.
BMI was positively correlated with ER+/PR+ and ER−/PR− subtype risks, with a significant association only seen for ER+/PR+ subtypes.
The researchers found that there was an association for multivitamin use before diagnosis with reduced symptoms of CIPN (CTCAE-adjusted odds ratio, 0.6 [95% confidence interval, 0.42 to 0.87]; FACT/GOG-Ntx-adjusted OR, 0.78 [95% confidence interval, 0.61 to 1]).
Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.
Using a handheld wireless remote control, the patient can adjust the compression force after breast positioning by a technologist.
The researchers recommend that women should not generally be treated with menopausal hormone therapy or tibolone following breast cancer, but should optimize lifestyle.
The approval was supported by data from the Phase 3 FALCON trial (n=462) that enrolled postmenopausal women with HR+ metastatic or locally advanced breast cancer.
The team found that breast cancer levels in premenopausal women who currently smoked or had smoked in the past grew by 14% if they were in the 20% deemed to have had the most exposure to outdoor light at night.
Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).
The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.
"Our data suggest that the OATP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans," the authors write.
The approval was supported by data from the Phase 3 multicenter, randomized, double-blind, placebo-controlled ExteNET trial (n=2,840) following adjuvant treatment with trastuzumab.
Two separate Biologics License Applications (BLAs) for biosimilar candidates to Herceptin (trastuzumab) have been submitted to the Food and Drug Administration (FDA).
At a median follow-up of 51 months, cancer recurrence developed in 17 patients. None of the recurrences involved nipples retained during mastectomies, the researchers found.
The invasive disease-free survival was reportedly 94.2% in Nerlynx-treated patients vs. 91.9% in placebo patients after 2 years (hazard ratio [HR] 0.66, 95% CI: 0.49, 0.90; P=0.008).
Herceptin, a human epidermal growth factor receptor (HER2) inhibitor, is currently approved to treat HER2-overexpressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination with paclitaxel in patients who have not received chemotherapy.
A study of 122 women with Stage I and Stage II breast cancer undergoing chemotherapy particularly associated with hair loss. The study showed that over 66% of patients using DigniCap reported losing less than half their hair.
The researchers found that the increase in breast cancer risk rose quickly in early adulthood and then plateaued, typically for the rest of a woman's life.
As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.
Overall, women with the highest amounts of daily activity were 13% less likely to develop postmenopausal breast cancer, versus women with the lowest activity levels.
For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.
Researchers asked 90 breast cancer survivors with insomnia and symptoms of depression and daytime sleepiness to undergo weekly cognitive behavioral therapy sessions or weekly classes in a Westernized form of tai chi.
These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression and cellular proliferation.
The only adverse event that was grade 3 or higher was fatigue with 16.3% incidence in the treatment group and 13.2% in the control group.
Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.